{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:24:40Z","timestamp":1784161480620,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16070-7","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:45:08Z","timestamp":1778046308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of advanced glycation end products and their receptors on the development and prognosis of colorectal cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Li-Juan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"16070_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023 May-Jun;73(3):233\u201354. https:\/\/doi.org\/10.3322\/caac.21772.","DOI":"10.3322\/caac.21772"},{"issue":"5","key":"16070_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584\u201390. https:\/\/doi.org\/10.1097\/CM9.0000000000002108.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"16070_CR3","doi-asserted-by":"publisher","first-page":"18867","DOI":"10.1038\/s41598-023-46348-w","volume":"13","author":"F Liu","year":"2023","unstructured":"Liu F, Huang Y, Li ZW, et al. Hyperuricemia remission after colorectal cancer surgery for colorectal cancer patients. Sci Rep. 2023;13(1):18867. https:\/\/doi.org\/10.1038\/s41598-023-46348-w.","journal-title":"Sci Rep"},{"issue":"10","key":"16070_CR4","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1080\/01635581.2023.2272815","volume":"75","author":"XR Liu","year":"2023","unstructured":"Liu XR, Liu F, Li ZW, et al. The Use of Metformin and Postoperative Insulin Pump Were Predictive Factors for Outcomes of Diabetic Colorectal Cancer Patients after Surgery. Nutr Cancer. 2023;75(10):1926\u201333. https:\/\/doi.org\/10.1080\/01635581.2023.2272815.","journal-title":"Nutr Cancer"},{"issue":"1","key":"16070_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1186\/s12885-023-11446-5","volume":"23","author":"XP Shu","year":"2023","unstructured":"Shu XP, Xiang YC, Liu F, et al. Effect of serum lactate dehydrogenase-to-albumin ratio (LAR) on the short-term outcomes and long-term prognosis of colorectal cancer after radical surgery. BMC Cancer. 2023;23(1):915. https:\/\/doi.org\/10.1186\/s12885-023-11446-5.","journal-title":"BMC Cancer"},{"issue":"12","key":"16070_CR6","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1007\/s10147-023-02410-1","volume":"28","author":"B Zhang","year":"2023","unstructured":"Zhang B, Li ZW, Tong Y, et al. The predictive value of advanced lung cancer inflammation index for short-term outcomes and prognosis of colorectal cancer patients who underwent radical surgery. Int J Clin Oncol. 2023;28(12):1616\u201324. https:\/\/doi.org\/10.1007\/s10147-023-02410-1.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"16070_CR7","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3390\/ijms25042228","volume":"25","author":"AG Papavassiliou","year":"2024","unstructured":"Papavassiliou AG, Delle Cave D. Novel Therapeutic Approaches for Colorectal Cancer Treatment. Int J Mol Sci. 2024;25(4):2228. https:\/\/doi.org\/10.3390\/ijms25042228.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"16070_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1\u201342. https:\/\/doi.org\/10.1007\/s10147-019-01485-z. Epub 2019 Jun 15.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"16070_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3945\/an.116.013912","volume":"8","author":"A Gugliucci","year":"2017","unstructured":"Gugliucci A. Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases. Adv Nutr. 2017;8(1):54\u201362. https:\/\/doi.org\/10.3945\/an.116.013912.","journal-title":"Adv Nutr"},{"issue":"8","key":"16070_CR10","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/cells11081312","volume":"11","author":"A Twarda-Clapa","year":"2022","unstructured":"Twarda-Clapa A, Olczak A, Bia\u0142kowska AM, et al. Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. Cells. 2022;11(8):1312. https:\/\/doi.org\/10.3390\/cells11081312.","journal-title":"Cells"},{"key":"16070_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12885-016-2213-5","volume":"16","author":"S Sakellariou","year":"2016","unstructured":"Sakellariou S, Fragkou P, Levidou G, et al. Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis. BMC Cancer. 2016;16:174. https:\/\/doi.org\/10.1186\/s12885-016-2213-5.","journal-title":"BMC Cancer"},{"key":"16070_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.redox.2013.12.016","volume":"2","author":"C Ott","year":"2014","unstructured":"Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411\u201329. https:\/\/doi.org\/10.1016\/j.redox.2013.12.016.","journal-title":"Redox Biol"},{"issue":"12","key":"16070_CR13","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/s0169-409x(02)00160-6","volume":"54","author":"D Stern","year":"2002","unstructured":"Stern D, Yan SD, Yan SF, et al. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev. 2002;54(12):1615\u201325. https:\/\/doi.org\/10.1016\/s0169-409x(02)00160-6.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"16070_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12672-018-0342-9","volume":"9","author":"G Palanissami","year":"2018","unstructured":"Palanissami G, Paul SFD. RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review. Horm Cancer. 2018;9(5):295\u2013325. https:\/\/doi.org\/10.1007\/s12672-018-0342-9.","journal-title":"Horm Cancer"},{"issue":"3","key":"16070_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1189\/jlb.0409230","volume":"86","author":"R Ramasamy","year":"2009","unstructured":"Ramasamy R, Yan SF, Schmidt AM. RAGE: therapeutic target and biomarker of the inflammatory response\u2013the evidence mounts. J Leukoc Biol. 2009;86(3):505\u201312. https:\/\/doi.org\/10.1189\/jlb.0409230.","journal-title":"J Leukoc Biol"},{"issue":"10","key":"16070_CR16","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1158\/0008-5472.CAN-15-0169","volume":"75","author":"DP Turner","year":"2015","unstructured":"Turner DP. Advanced glycation end-products: a biological consequence of lifestyle contributing to cancer disparity. Cancer Res. 2015;75(10):1925\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0169.","journal-title":"Cancer Res"},{"key":"16070_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1478-811X-7-12","volume":"7","author":"A Riehl","year":"2009","unstructured":"Riehl A, N\u00e9meth J, Angel P, et al. The receptor RAGE: Bridging inflammation and cancer. Cell Commun Signal. 2009;7:12. https:\/\/doi.org\/10.1186\/1478-811X-7-12.","journal-title":"Cell Commun Signal"},{"issue":"4","key":"16070_CR18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.2741\/e178","volume":"2","author":"S Yamagishi","year":"2010","unstructured":"Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed). 2010;2(4):1184\u201395. https:\/\/doi.org\/10.2741\/e178.","journal-title":"Front Biosci (Elite Ed)"},{"key":"16070_CR19","doi-asserted-by":"publisher","first-page":"1125745","DOI":"10.3389\/fonc.2023.1125745","volume":"13","author":"Z Chen","year":"2023","unstructured":"Chen Z, Hong Q. Correlation of serum IGF-1, AGEs and their receptors with the risk of colorectal cancer in patients with type 2 diabetes mellitus. Front Oncol. 2023;13:1125745. https:\/\/doi.org\/10.3389\/fonc.2023.1125745.","journal-title":"Front Oncol"},{"issue":"10","key":"16070_CR20","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.18632\/oncotarget.1908","volume":"5","author":"M Dahlmann","year":"2014","unstructured":"Dahlmann M, Okhrimenko A, Marcinkowski P, et al. RAGE mediates S100A4-induced cell motility via MAPK\/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis. Oncotarget. 2014;5(10):3220\u201333. https:\/\/doi.org\/10.18632\/oncotarget.1908.","journal-title":"Oncotarget"},{"issue":"7","key":"16070_CR21","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1158\/1055-9965","volume":"20","author":"L Jiao","year":"2011","unstructured":"Jiao L, Taylor PR, Weinstein SJ, et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1430\u20138. https:\/\/doi.org\/10.1158\/1055-9965.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"16070_CR22","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1007\/s13277-013-1414-7","volume":"35","author":"F Qian","year":"2014","unstructured":"Qian F, Sun BL, Zhang WY, et al. Gly82Ser polymorphism of the receptor for advanced glycation end-product (RAGE) potential high risk in patients with colorectal cancer. Tumour Biol. 2014;35(4):3171\u20135. https:\/\/doi.org\/10.1007\/s13277-013-1414-7.","journal-title":"Tumour Biol"},{"issue":"1","key":"16070_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/1055-9965.EPI-20-0855","volume":"30","author":"EK Aglago","year":"2021","unstructured":"Aglago EK, Rinaldi S, Freisling H, et al. Soluble Receptor for Advanced Glycation End-products (sRAGE) and Colorectal Cancer Risk: A Case-Control Study Nested within a European Prospective Cohort. Cancer Epidemiol Biomarkers Prev. 2021;30(1):182\u201392. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-0855.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"16070_CR24","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906.","journal-title":"Int J Surg"},{"key":"16070_CR25","unstructured":"Wells G, Shea B, O\u2019Connell D et al. Accessed October 30,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (2020)."},{"issue":"5","key":"16070_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1365-2753.2008.00986.x","volume":"14","author":"JP Ioannidis","year":"2008","unstructured":"Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14(5):951\u20137. https:\/\/doi.org\/10.1111\/j.1365-2753.2008.00986.x.","journal-title":"J Eval Clin Pract"},{"issue":"5","key":"16070_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/carcin\/bgab026","volume":"42","author":"EK Aglago","year":"2021","unstructured":"Aglago EK, Schalkwijk CG, Freisling H, et al. Plasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study. Carcinogenesis. 2021;42(5):705\u201313. https:\/\/doi.org\/10.1093\/carcin\/bgab026. PMID: 33780524IF: 2.9 Q2 B3; PMCID: PMC8162627IF: 2.9 Q2 B3.","journal-title":"Carcinogenesis"},{"key":"16070_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.canep.2016.04.004","volume":"42","author":"L Chen","year":"2016","unstructured":"Chen L, Duan Z, Tinker L, et al. A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women. Cancer Epidemiol. 2016;42:115\u201323.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"16070_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12902-020-00647-9","volume":"20","author":"X Zhou","year":"2020","unstructured":"Zhou X, Lin N, Zhang M, Wang X, An Y, Su Q, Du P, Li B, Chen H. Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer. BMC Endocr Disord. 2020;20(1):170. https:\/\/doi.org\/10.1186\/s12902-020-00647-9. PMID: 33187505IF: 3.3 Q2 B3; PMCID: PMC7666469IF: 3.3 Q2 B3.","journal-title":"BMC Endocr Disord"},{"key":"16070_CR30","doi-asserted-by":"publisher","first-page":"4889616","DOI":"10.1155\/2022\/4889616","volume":"2022","author":"XC Liu","year":"2022","unstructured":"Liu XC, Dai YL, Huang F, et al. Diagnostic Value of Carcinoembryonic Antigen Combined with Multi-Inflammatory Cell Ratios in Colorectal Cancer. Dis Markers. 2022;2022:4889616. https:\/\/doi.org\/10.1155\/2022\/4889616.","journal-title":"Dis Markers"},{"issue":"11","key":"16070_CR31","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.cellsig.2013.06.013","volume":"25","author":"J Xie","year":"2013","unstructured":"Xie J, M\u00e9ndez JD, M\u00e9ndez-Valenzuela V, et al. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal. 2013;25(11):2185\u201397. https:\/\/doi.org\/10.1016\/j.cellsig.2013.06.013.","journal-title":"Cell Signal"},{"issue":"10","key":"16070_CR32","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00535-012-0572-5","volume":"47","author":"T Shimomoto","year":"2012","unstructured":"Shimomoto T, Luo Y, Ohmori H, et al. Advanced glycation end products (AGE) induce the receptor for AGE in the colonic mucosa of azoxymethane-injected Fischer 344 rats fed with a high-linoleic acid and high-glucose diet. J Gastroenterol. 2012;47(10):1073\u201383. https:\/\/doi.org\/10.1007\/s00535-012-0572-5.","journal-title":"J Gastroenterol"},{"issue":"3","key":"16070_CR33","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1371\/journal.pmed.0030047","volume":"3","author":"JT Chi","year":"2006","unstructured":"Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3(3):e47. https:\/\/doi.org\/10.1371\/journal.pmed.0030047.","journal-title":"PLoS Med"},{"issue":"1","key":"16070_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1042\/BJ20120298","volume":"448","author":"S Grimm","year":"2012","unstructured":"Grimm S, Ott C, H\u00f6rlacher M, et al. Advanced-glycation-end-product-induced formation of immunoproteasomes: involvement of RAGE and Jak2\/STAT1. Biochem J. 2012;448(1):127\u201339. https:\/\/doi.org\/10.1042\/BJ20120298.","journal-title":"Biochem J"},{"key":"16070_CR35","doi-asserted-by":"publisher","first-page":"7026","DOI":"10.12659\/MSM.916260","volume":"25","author":"Y Xu","year":"2019","unstructured":"Xu Y, Lu Z, Shen N, et al. Association of RAGE rs1800625 Polymorphism and Cancer Risk: A Meta-Analysis of 18 Case-Control Studies. Med Sci Monit. 2019;25:7026\u201334. https:\/\/doi.org\/10.12659\/MSM.916260.","journal-title":"Med Sci Monit"},{"issue":"12","key":"16070_CR36","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1158\/1055-9965.EPI-15-0422","volume":"24","author":"SY Kong","year":"2015","unstructured":"Kong SY, Takeuchi M, Hyogo H, et al. The Association between Glyceraldehyde-Derived Advanced Glycation End-Products and Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2015;24(12):1855\u201363. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0422.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"16070_CR37","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/cc9990","volume":"15","author":"MA van Zoelen","year":"2011","unstructured":"van Zoelen MA, Achouiti A, van der Poll T. The role of receptor for advanced glycation endproducts (RAGE) in infection. Crit Care. 2011;15(2):208. https:\/\/doi.org\/10.1186\/cc9990. Epub 2011 Mar 22.","journal-title":"Crit Care"},{"issue":"4","key":"16070_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/embor.2011.28","volume":"12","author":"M He","year":"2011","unstructured":"He M, Kubo H, Morimoto K, et al. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep. 2011;12(4):358\u201364. https:\/\/doi.org\/10.1038\/embor.2011.28.","journal-title":"EMBO Rep"},{"issue":"9","key":"16070_CR39","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/onc.2012.119","volume":"32","author":"J Heijmans","year":"2013","unstructured":"Heijmans J, B\u00fcller NV, Hoff E, et al. Rage signalling promotes intestinal tumourigenesis. Oncogene. 2013;32(9):1202\u20136. https:\/\/doi.org\/10.1038\/onc.2012.119.","journal-title":"Oncogene"},{"issue":"10","key":"16070_CR40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri1703","volume":"5","author":"M Karin","year":"2005","unstructured":"Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749\u201359. https:\/\/doi.org\/10.1038\/nri1703.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"16070_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11739-009-0300-1","volume":"4","author":"N Vazzana","year":"2009","unstructured":"Vazzana N, Santilli F, Cuccurullo C, et al. Soluble forms of RAGE in internal medicine. Intern Emerg Med. 2009;4(5):389\u2013401. https:\/\/doi.org\/10.1007\/s11739-009-0300-1. Epub 2009 Sep 2.","journal-title":"Intern Emerg Med"},{"issue":"8","key":"16070_CR42","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2174\/092986709787581888","volume":"16","author":"F Santilli","year":"2009","unstructured":"Santilli F, Vazzana N, Bucciarelli LG, et al. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem. 2009;16(8):940\u201352. https:\/\/doi.org\/10.2174\/092986709787581888.","journal-title":"Curr Med Chem"},{"issue":"10","key":"16070_CR43","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1096\/fj.08-109033","volume":"22","author":"A Raucci","year":"2008","unstructured":"Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008;22(10):3716\u201327. https:\/\/doi.org\/10.1096\/fj.08-109033.","journal-title":"FASEB J"},{"key":"16070_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1479-5876-7-17","volume":"7","author":"LJ Sparvero","year":"2009","unstructured":"Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009;7:17. https:\/\/doi.org\/10.1186\/1479-5876-7-17.","journal-title":"J Transl Med"},{"issue":"6","key":"16070_CR45","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/ijc.11016","volume":"104","author":"H Kuniyasu","year":"2003","unstructured":"Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer. 2003;104(6):722\u20137. https:\/\/doi.org\/10.1002\/ijc.11016.","journal-title":"Int J Cancer"},{"issue":"1","key":"16070_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4149\/neo_2010_01_055","volume":"57","author":"R Jing","year":"2010","unstructured":"Jing R, Cui M, Wang J, et al. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma. 2010;57(1):55\u201361. https:\/\/doi.org\/10.4149\/neo_2010_01_055.","journal-title":"Neoplasma"},{"issue":"5","key":"16070_CR47","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1002\/cam4.1426","volume":"7","author":"DL White","year":"2018","unstructured":"White DL, Hoogeveen RC, Chen L, et al. A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. Cancer Med. 2018;7(5):2180\u201391. https:\/\/doi.org\/10.1002\/cam4.1426. Epub 2018 Mar 23.","journal-title":"Cancer Med"},{"issue":"11","key":"16070_CR48","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","volume":"83","author":"A Bierhaus","year":"2005","unstructured":"Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl). 2005;83(11):876\u201386. https:\/\/doi.org\/10.1007\/s00109-005-0688-7.","journal-title":"J Mol Med (Berl)"},{"issue":"10","key":"16070_CR49","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.bcp.2010.01.013","volume":"79","author":"SF Yan","year":"2010","unstructured":"Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: terapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol. 2010;79(10):1379\u201386. https:\/\/doi.org\/10.1016\/j.bcp.2010.01.013.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"16070_CR50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4149\/neo_2010_01_055","volume":"57","author":"R Jing","year":"2010","unstructured":"Jing R, Cui M, Wang J, et al. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma. 2010;57(1):55\u201361. https:\/\/doi.org\/10.4149\/neo_2010_01_055.","journal-title":"Neoplasma"},{"issue":"4","key":"16070_CR51","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.2741\/e178","volume":"2","author":"S Yamagishi","year":"2010","unstructured":"Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed). 2010;2(4):1184\u201395. https:\/\/doi.org\/10.2741\/e178.","journal-title":"Front Biosci (Elite Ed)"},{"issue":"9","key":"16070_CR52","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","volume":"2","author":"Y Xia","year":"2014","unstructured":"Xia Y, Shen S, Verma IM. NF-\u03baB, an active player in human cancers. Cancer Immunol Res. 2014;2(9):823\u201330. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0112.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"16070_CR53","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12902-020-00647-9","volume":"20","author":"X Zhou","year":"2020","unstructured":"Zhou X, Lin N, Zhang M, et al. Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer. BMC Endocr Disord. 2020;20(1):170. https:\/\/doi.org\/10.1186\/s12902-020-00647-9.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"16070_CR54","doi-asserted-by":"publisher","first-page":"29500","DOI":"10.1038\/s41598-025-15309-w","volume":"15","author":"K Wang","year":"2025","unstructured":"Wang K, Li K, Zhang Z, et al. Combined preoperative platelet-albumin ratio and cancer inflammation prognostic index predicts prognosis in colorectal cancer: a retrospective study. Sci Rep. 2025;15(1):29500. https:\/\/doi.org\/10.1038\/s41598-025-15309-w.","journal-title":"Sci Rep"},{"issue":"1","key":"16070_CR55","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1186\/s12885-025-15165-x","volume":"25","author":"K Li","year":"2025","unstructured":"Li K, Zhang R, Zhang J, et al. The prognostic role of inflammation-based hematologic markers in stage I-III colorectal cancer: a retrospective analysis. BMC Cancer. 2025;25(1):1822. https:\/\/doi.org\/10.1186\/s12885-025-15165-x.","journal-title":"BMC Cancer"},{"issue":"10","key":"16070_CR56","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.4240\/wjgs.v16.i10.3142","volume":"16","author":"P Shayimu","year":"2024","unstructured":"Shayimu P, Awula M, Wang CY, et al. Serum nutritional predictive biomarkers and risk assessment for anastomotic leakage after laparoscopic surgery in rectal cancer patients. World J Gastrointest Surg. 2024;16(10):3142\u201354. https:\/\/doi.org\/10.4240\/wjgs.v16.i10.3142.","journal-title":"World J Gastrointest Surg"},{"issue":"21","key":"16070_CR57","doi-asserted-by":"publisher","first-page":"e71317","DOI":"10.1002\/cam4.71317","volume":"14","author":"Y Chen","year":"2025","unstructured":"Chen Y, Bai M, Liu M, et al. Metabolic Reprogramming in Lung Cancer: Hallmarks, Mechanisms, and Targeted Strategies to Overcome Immune Resistance. Cancer Med. 2025;14(21):e71317. https:\/\/doi.org\/10.1002\/cam4.71317.","journal-title":"Cancer Med"},{"issue":"6","key":"16070_CR58","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/hep.26264","volume":"57","author":"KA Moy","year":"2013","unstructured":"Moy KA, Jiao L, Freedman ND, et al. Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology. 2013;57(6):2338\u201345. https:\/\/doi.org\/10.1002\/hep.26264.","journal-title":"Hepatology"},{"issue":"9","key":"16070_CR59","doi-asserted-by":"publisher","first-page":"8749","DOI":"10.1007\/s13277-014-2122-7","volume":"35","author":"L He","year":"2014","unstructured":"He L, Bao H, Xue J, et al. Circulating soluble advanced glycation end product is inversely associated with the significant risk of developing cancer: evidence from a meta-analysis. Tumour Biol. 2014;35(9):8749\u201355. https:\/\/doi.org\/10.1007\/s13277-014-2122-7.","journal-title":"Tumour Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16070-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16070-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:17:23Z","timestamp":1782872243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16070-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16070"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16070-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"789"}}